Springer Nature is making SARS-CoV-2 and COVID-19 research free.
View research |
View latest news |
Sign up for updates
From: A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis